AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32747306 — intervention group
Group type: COMPARATOR
Intervention: CBFS (Tachosil®)
Number of subjects: 150
Study 32909387 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard provider-initiated-testing-and-counselling (PITC)
Number of subjects: 15
Study 32909387 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized PITC (additional provider training and job-aids)
Number of subjects: 15
Study 32909387 — intervention group
Group type: EXPERIMENTAL
Intervention: FB-HIVST (HIVST demonstration, distribution and kit use in OPD, private kit interpretation and optional HIV counselling)
Number of subjects: 15
Study 32909387 — intervention group
Group type: COMPARATOR
Intervention: Optimized PITC
Number of subjects: 15
Study 32909387 — intervention group
Group type: COMPARATOR
Intervention: FB-HIVST
Number of subjects: 15
Study 35677588 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation audio-recordings with an interpreter and question prompt lists translated into Arabic, Greek, Traditional, and Simplified Chinese.
Number of subjects: 0
Study 35677588 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation audio-recordings with an interpreter and question prompt lists.
Number of subjects: 0
Study 35677588 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (feasibility study).
Number of subjects: 0
Study 34074214 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) with 25 daily multi-donor FMT capsules for 12 days
Number of subjects: 0
Study 34074214 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 0
Study 36577981 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates with HIE (study group)
Number of subjects: 90
Study 36577981 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates with HIE (severe group)
Number of subjects: 90
Study 36577981 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates with HIE (mild group)
Number of subjects: 90
Study 34530839 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic driver assistance module of powered wheelchair (PWC)
Number of subjects: 23
Study 34530839 — intervention group
Group type: COMPARATOR
Intervention: No assistance (control)
Number of subjects: 23
Study 33756097 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw exercise (JE) intervention program combined with an information/counselling program (IC)
Number of subjects: 83
Study 33756097 — intervention group
Group type: COMPARATOR
Intervention: Information/counselling alone (IC)
Number of subjects: 83
Study 32409277 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital Adrenal Hyperplasia (CAH)
Number of subjects: 1628
Study 32409277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Gonadal Dysgenesis (MGD)
Number of subjects: 1628
Study 32409277 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Androgen Insensitivity Syndrome (PAIS)
Number of subjects: 1628
Study 32409277 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall utility value
Number of subjects: 1628
Study 32409277 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender identity concerns
Number of subjects: 1628
Study 32409277 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary function concerns
Number of subjects: 1628
Study 32409277 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical complications concerns
Number of subjects: 1628
Study 32409277 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for early surgical intervention
Number of subjects: 1628
Study 32409277 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for delayed surgical intervention
Number of subjects: 1628
Study 35869616 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day aspirin
Number of subjects: 0
Study 35869616 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-day aspirin + 3-day clopidogrel
Number of subjects: 0
Study 35869616 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day aspirin + 7-day clopidogrel
Number of subjects: 0
Study 35869616 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-day aspirin + 7-day clopidogrel
Number of subjects: 0
Study 33990843 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐cigarettes shown on Instagram
Number of subjects: 928
Study 32295718 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose influenza vaccine (HD) - Sanofi Pasteur Fluzone High Dose [60 mcg × 3 strains]
Number of subjects: 0
Study 32295718 — intervention group
Group type: COMPARATOR
Intervention: Standard dose influenza vaccine (SD) - Sanofi Pasteur Fluzone® [15 mcg × 3 strains]
Number of subjects: 0
Study 36141714 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training program
Number of subjects: 74
Study 36141714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mindfulness training)
Number of subjects: 74
Study 34036644 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-MAC
Number of subjects: 36
Study 34036644 — intervention group
Group type: COMPARATOR
Intervention: MAC
Number of subjects: 36
Study 34036644 — intervention group
Group type: COMPARATOR
Intervention: UTM
Number of subjects: 36
Study 34036644 — intervention group
Group type: COMPARATOR
Intervention: Plasma-UTM
Number of subjects: 36
Study 34036644 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-abutments
Number of subjects: 36
Study 34036644 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study 34145518 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational Agent + TAU
Number of subjects: 178
Study 34145518 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 178
Study 34410635 — intervention group
Group type: EXPERIMENTAL
Intervention: KdD
Number of subjects: 66
Study 34410635 — intervention group
Group type: COMPARATOR
Intervention: Kd
Number of subjects: 66
Study 35183448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 110
Study 35183448 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia (PCEA)
Number of subjects: 110
Study 33096271 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 43
Study 33096271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 33096271 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin and Placebo (combined analysis)
Number of subjects: 43
Study 32030573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicosulfuron at 6 g a.e. ha‐1
Number of subjects: 5
Study 32030573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicosulfuron at 12 g a.e. ha‐1
Number of subjects: 5
Study 32030573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicosulfuron at 24 g a.e. ha‐1
Number of subjects: 5
Study 32030573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicosulfuron at 48 g a.e. ha‐1
Number of subjects: 5
Study 32030573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicosulfuron at 60 g a.e. ha‐1
Number of subjects: 5
Study 32030573 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g a.e. ha‐1)
Number of subjects: 5
Study 36108923 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg once daily
Number of subjects: 0
Study 36108923 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg once daily
Number of subjects: 0
Study 36108923 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 0
Study 36108923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34787246 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate (CHX)
Number of subjects: 48
Study 34787246 — intervention group
Group type: COMPARATOR
Intervention: Control (without pre-treatment)
Number of subjects: 48
Study 32039716 — intervention group
Group type: EXPERIMENTAL
Intervention: High HIV-related stigma (score ≥ 27)
Number of subjects: 367
Study 32039716 — intervention group
Group type: EXPERIMENTAL
Intervention: High MSM-related stigma (score ≥ 6)
Number of subjects: 367
Study 32039716 — intervention group
Group type: EXPERIMENTAL
Intervention: Any IPV
Number of subjects: 367
Study 32039716 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical IPV
Number of subjects: 367
Study 32039716 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological IPV
Number of subjects: 367
Study 32039716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual IPV
Number of subjects: 367
Study 35933942 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release injectable naltrexone (XR-NTX) before release
Number of subjects: 86
Study 35933942 — intervention group
Group type: COMPARATOR
Intervention: Extended-release injectable naltrexone (XR-NTX) referral after release
Number of subjects: 86
Study 34477015 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying signs
Number of subjects: 24
Study 34477015 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative signs
Number of subjects: 24
Study 34477015 — intervention group
Group type: EXPERIMENTAL
Intervention: Architectural features
Number of subjects: 24
Study 34477015 — intervention group
Group type: EXPERIMENTAL
Intervention: Four types of signage (identifying signs, informative signs, directional, and safety/regulatory signs)
Number of subjects: 24
Study 32971192 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly created AVFs in Japan
Number of subjects: 2040
Study 32971192 — intervention group
Group type: COMPARATOR
Intervention: Newly created AVFs in EUR/ANZ and US
Number of subjects: 2040
Study 32971192 — intervention group
Group type: EXPERIMENTAL
Intervention: Not using an arteriovenous access within 6 months of AVF creation
Number of subjects: 2040
Study 33158101 — intervention group
Group type: EXPERIMENTAL
Intervention: DAGIS intervention
Number of subjects: 0
Study 33158101 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33158101 — intervention group
Group type: COMPARATOR
Intervention: High PEL control group
Number of subjects: 0
Study 34783956 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care together with use of the PROMPT‐QoL
Number of subjects: 286
Study 34783956 — intervention group
Group type: COMPARATOR
Intervention: Pharmaceutical care only
Number of subjects: 286
Study 33277746 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA/MPA
Number of subjects: 151
Study 33277746 — intervention group
Group type: EXPERIMENTAL
Intervention: EVL/MPA/steroids
Number of subjects: 151
Study 34627499 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship intervention (education, engaging opinion leaders, prospective audit and feedback of antibiotic use)
Number of subjects: 4084
Study 34627499 — intervention group
Group type: COMPARATOR
Intervention: Control period (broad-spectrum antibiotics)
Number of subjects: 4084
Study 34627499 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention period (antibiotic stewardship)
Number of subjects: 4084
Study 34481407 — intervention group
Group type: EXPERIMENTAL
Intervention: CyclASol 0.1%
Number of subjects: 328
Study 34481407 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 328
Study 35555211 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Follicular (EF) phase
Number of subjects: 8
Study 35555211 — intervention group
Group type: EXPERIMENTAL
Intervention: Late Follicular (LF) phase
Number of subjects: 8
Study 35555211 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-Luteal (ML) phase
Number of subjects: 8
Study 33069259 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for predicting overall survival (OS)
Number of subjects: 1541
Study 33069259 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for predicting cancer-specific survival (CSS)
Number of subjects: 1541
Study 33069259 — intervention group
Group type: COMPARATOR
Intervention: Nomograms compared to AJCC staging system
Number of subjects: 1541
Study 36481522 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate and nicardipine (combination therapy)
Number of subjects: 1523
Study 36481522 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate alone (control)
Number of subjects: 1523
Study 34836856 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5-10mg
Number of subjects: 0
Study 34836856 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 25-50mg
Number of subjects: 0
Study 36371234 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab and rituximab combined with standard of care (prednisolone and mycophenolate)
Number of subjects: 70
Study 36371234 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (prednisolone and mycophenolate)
Number of subjects: 70
Study 34034418 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg/day
Number of subjects: 132
Study 34034418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 36127081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention called SmartSafe in addition to treatment as usual (TAU)
Number of subjects: 0
Study 36127081 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) with monitoring using Ecological Momentary Assessment (EMA)
Number of subjects: 0
Study 34607597 — intervention group
Group type: EXPERIMENTAL
Intervention: Free gingival graft (FGG) before implant placement
Number of subjects: 26
Study 34607597 — intervention group
Group type: COMPARATOR
Intervention: Control group (without FGG before implant placement)
Number of subjects: 26
Study 32842983 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum multinutrient formula for 12 weeks
Number of subjects: 120
Study 32842983 — intervention group
Group type: COMPARATOR
Intervention: Active control formula containing iodine and riboflavin for 12 weeks
Number of subjects: 120
Study 36138381 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo education (n=49)
Number of subjects: 100
Study 36138381 — intervention group
Group type: COMPARATOR
Intervention: Attention control (n=51)
Number of subjects: 100
Study 33197414 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg IV ibuprofen
Number of subjects: 40
Study 33197414 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mL saline)
Number of subjects: 40
Study 35777250 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) biofeedback treatment including at-home breathing practice
Number of subjects: 21
Study 35777250 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 21
Study 32144896 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight loss (D) + Exercise (E)
Number of subjects: 343
Study 32144896 — intervention group
Group type: COMPARATOR
Intervention: Dietary weight loss (D)
Number of subjects: 343
Study 32144896 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple outcome random forest model
Number of subjects: 343
Study 32144896 — intervention group
Group type: EXPERIMENTAL
Intervention: List-based models
Number of subjects: 343
Study 33263669 — intervention group
Group type: EXPERIMENTAL
Intervention: HF 20s + silanization
Number of subjects: 120
Study 33263669 — intervention group
Group type: EXPERIMENTAL
Intervention: HF 60s + silanization
Number of subjects: 120
Study 33263669 — intervention group
Group type: EXPERIMENTAL
Intervention: HF 120s + silanization
Number of subjects: 120
Study 33263669 — intervention group
Group type: EXPERIMENTAL
Intervention: HF 120s + SBU
Number of subjects: 120
Study 33263669 — intervention group
Group type: EXPERIMENTAL
Intervention: HF 120s
Number of subjects: 120
Study 33263669 — intervention group
Group type: EXPERIMENTAL
Intervention: MEP
Number of subjects: 120
Study 33263669 — intervention group
Group type: COMPARATOR
Intervention: HF 20s + SBU
Number of subjects: 120
Study 33263669 — intervention group
Group type: EXPERIMENTAL
Intervention: HF 20s
Number of subjects: 120
Study 35524833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (30 min of aerobic exercise using a cycle ergometer and resistance training with elastic tube, three times per week for 1 year)
Number of subjects: 46
Study 35524833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise
Number of subjects: 46
Study 35524833 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 46
Study 34757341 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (n=20)
Number of subjects: 40
Study 34757341 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (n=20)
Number of subjects: 40
Study 32235518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic low-carbohydrate high-fat (LCHF) diet
Number of subjects: 24
Study 32235518 — intervention group
Group type: COMPARATOR
Intervention: Control diet (National Food Agency recommended diet)
Number of subjects: 24
Study 34407033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 34407033 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pain variability (coefficient of variation, SD, difference between highest and lowest NRS score)
Number of subjects: 160
Study 34165508 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of zoledronate treatment (4 mg intravenously every 3 months for 2 years, followed by 4 mg intravenously every 6 months for 3 years)
Number of subjects: 3754
Study 34165508 — intervention group
Group type: COMPARATOR
Intervention: 2 years of zoledronate treatment (4 mg intravenously every 3 months for 2 years)
Number of subjects: 3754
Study 34165508 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of zoledronate treatment
Number of subjects: 3754
Study 34165508 — intervention group
Group type: COMPARATOR
Intervention: 2 years of zoledronate treatment
Number of subjects: 3754
Study 33272042 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaempferia parviflora extract (360 mg/day)
Number of subjects: 194
Study 33272042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 34560841 — intervention group
Group type: EXPERIMENTAL
Intervention: LF‐rTMS+cTBS group (n=30)
Number of subjects: 90
Study 34560841 — intervention group
Group type: COMPARATOR
Intervention: LF‐rTMS group (n=30)
Number of subjects: 90
Study 34560841 — intervention group
Group type: COMPARATOR
Intervention: cTBS group (n=30)
Number of subjects: 90
Study 32740578 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominoplasty with preservation of Scarpa fascia (group B)
Number of subjects: 160
Study 32740578 — intervention group
Group type: COMPARATOR
Intervention: Classic full abdominoplasty (group A)
Number of subjects: 160
Study 34181888 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Number of subjects: 44
Study 34181888 — intervention group
Group type: COMPARATOR
Intervention: Tactile-kinesthetic stimulation
Number of subjects: 44
Study 33915150 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision surgery
Number of subjects: 3717
Study 33915150 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer thrombin time (TT)
Number of subjects: 3717
Study 33915150 — intervention group
Group type: EXPERIMENTAL
Intervention: Using more than one gelatin sponge or using styptic powder in the surgery
Number of subjects: 3717
Study 33915150 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without reoperations)
Number of subjects: 3717
Study 34016612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotadutide 100 μg
Number of subjects: 834
Study 34016612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotadutide 200 μg
Number of subjects: 834
Study 34016612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotadutide 300 μg
Number of subjects: 834
Study 34016612 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 834
Study 34016612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 834
Study 33264337 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg twice for 1 day or HCQ 200 mg twice daily for 6 days
Number of subjects: 33
Study 33264337 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 33
Study 33264337 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 33
Study 33264337 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 36229051 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Number of subjects: 40
Study 36229051 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based heart failure treatment alone (Control)
Number of subjects: 40
Study 34454875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic cardiomyopathy (ICM)
Number of subjects: 4803
Study 34454875 — intervention group
Group type: COMPARATOR
Intervention: Nonischemic cardiomyopathy (NICM)
Number of subjects: 4803
Study 32342101 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS on the prefrontal cortex
Number of subjects: 124
Study 32342101 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 124
Study 32152503 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg I.V. every 3 weeks
Number of subjects: 29
Study 32152503 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 29
Study 33626326 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Oxygen Jet Therapy (TOJT)
Number of subjects: 73
Study 33626326 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 73
Study 35851027 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced case detection using LAMP technology, microscopy, and rapid diagnostic test for malaria at each antenatal care visit
Number of subjects: 2583
Study 35851027 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (venous blood sample for malaria diagnosis only in symptomatic patients)
Number of subjects: 2583
Study 33719833 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 + 3 induction
Number of subjects: 1247
Study 36124112 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sesame oil
Number of subjects: 120
Study 36124112 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 120
Study 32359042 — intervention group
Group type: EXPERIMENTAL
Intervention: eCHECKUP TO GO intervention
Number of subjects: 311
Study 32359042 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 311
Study 36235739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (school-based and home-based interventions to reduce SSB consumption)
Number of subjects: 1633